2021
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clinical Cancer Research 2021, 27: 6156-6163. PMID: 34465600, PMCID: PMC8595766, DOI: 10.1158/1078-0432.ccr-21-2103.Peer-Reviewed Original ResearchConceptsDisease-free survivalHER2-positive breast cancerShorter disease-free survivalBreast cancerQuantitative immunofluorescenceEarly-stage HER2-positive breast cancerAlpha-smooth muscle actin expressionAlpha-smooth muscle actinProgesterone receptor statusHigh α-SMA expressionDigital Spatial ProfilerΑ-SMA expressionPromising candidate biomarkerCompanion diagnostic testsMuscle actin expressionDigital spatial profilingCohort validationNeoadjuvant lapatinibAdjuvant trastuzumabReceptor statusClinical trialsUnivariate analysisEstrogen receptorMAIN OUTCOMEΑ-SMA
2019
Fractional Deletion of Compound Kushen Injection Indicates Cytokine Signaling Pathways are Critical for its Perturbation of the Cell Cycle
Aung TN, Nourmohammadi S, Qu Z, Harata-Lee Y, Cui J, Shen HY, Yool AJ, Pukala T, Du H, Kortschak RD, Wei W, Adelson DL. Fractional Deletion of Compound Kushen Injection Indicates Cytokine Signaling Pathways are Critical for its Perturbation of the Cell Cycle. Scientific Reports 2019, 9: 14200. PMID: 31578346, PMCID: PMC6775143, DOI: 10.1038/s41598-019-50271-4.Peer-Reviewed Original ResearchConceptsCompound Kushen InjectionExperimental biology approachesEffect of CKIPlant secondary metabolitesCytokine Signaling PathwaysCKI activityBiology approachReconstitution approachGene expressionCell cyclePhenotype dataSignaling pathwaysSecondary metabolitesBreast cancer cell linesCancer cell linesKushen InjectionSingle major compoundCell linesApoptosisLiquid chromatography fractionationCell viabilityHigh-performance liquid chromatography fractionationMajor compoundsComplex fashionCandidate mechanism
2016
Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics
Qu Z, Cui J, Harata-Lee Y, Aung TN, Feng Q, Raison JM, Kortschak RD, Adelson DL. Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics. Oncotarget 2016, 7: 66003-66019. PMID: 27602759, PMCID: PMC5323210, DOI: 10.18632/oncotarget.11788.Peer-Reviewed Original ResearchConceptsCompound Kushen InjectionAnti-cancer molecular mechanismMolecular mechanismsHigh-throughput Illumina RNA-Seq technologyIllumina RNA-Seq technologyMCF-7 cellsKushen InjectionRNA-seq technologyEffect of CKITranscriptome analysis methodsLong non-coding RNAsPlant secondary metabolitesNon-coding RNAsDifferential expression analysisCell proliferationGene differential expression analysisMCF-7 human breast cancer cell lineDe novo identificationHuman breast cancer cell linesMCF-7 cell proliferationBreast cancer cell linesDose-dependent fashionAnnexin V/propidium iodideTraditional Chinese medicine preparationP53-independent mechanism